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Background: The lipogenic transcription factor carbohydrate response element-binding protein (ChREBP) may play a key role in
malignant progression of breast cancer by allowing metabolic adaptations to take place in response to changes in oxygenation.
Methods: Immunohistochemical analysis of ChREBP was carried out in human breast tumour tissue microarrays representative of
malignant progression from normal breast through to metastatic cancer. The ChREBP protein and mRNA expressions were then
analysed in a series of breast cancers for correlative analysis with common and breast-specific hypoxia signatures, and survival.
Results: In invasive ductal carcinoma, ChREBP correlated significantly with mean ‘downregulated’ hypoxia scores
(r¼ 0.3, Po0.015, n¼ 67) and in two distinct breast progression arrays, ChREBP protein also increased with malignant progression
(Po0.001). However, bioinformatic analysis of a large data set (2136 cases) revealed an apparent reversal in the relationship
between ChREBP mRNA level and clinical outcome – not only being significantly correlated with increased survival
(log rank Po0.001), but also downregulated in malignant tissue compared with adjacent normal tissue.
Conclusion: The ChREBP expression may be reflective of an aerobic metabolic phenotype that may conflict with hypoxia-induced
signalling but provide a mechanism for growth at the oxygenated edge of the tumours.
The carbohydrate response element-binding protein (ChREBP) is a
glucose-regulated basic helix–loop–helix (bHLH) transcription
factor that acts as a key regulator of enzymes involved in fatty
acid synthesis. In response to increased glucose levels, ChREBP
undergoes dephosphorylation steps that allow translocation from
the cytoplasm to the nucleus where, in association with its binding
partner MLX (Max-like interacting protein), it binds to the
carbohydrate response element of lipogenic genes (Uyeda et al,
2002; Dentin et al, 2005b; Postic et al, 2007).
Evidence indicates that ChREBP may have a role in cancer
pathology and the mechanisms associated with tumourigenesis.
In particular, a link between ChREBP and the suppression of
p53-induced cell cycle arrest has been revealed in transformed cells
that takes place via the reprogramming of metabolism to favour
aerobic glycolysis (Tong et al, 2009), an established hallmark of
tumour metabolism (Airley and Mobasheri, 2007; Annibaldi and
Widmann, 2010; Scatena et al, 2010; Bensinger and Christofk,
2012). Furthermore, genomic analysis of ChREBP target gene
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expression in the hepatoma HEPG2 cell line shows a dual
association with pathways associated with the tumour metabolic
phenotype as well as with malignant progression, such as
differentiation and motility (Jeong et al, 2011).
The metabolic shift from one that is dominated by oxidative
phosphorylation to that of increased glycolytic flux is manifested
by increased glucose flux and often overexpression of the hypoxia-
inducible factor-1 (HIF-1)- regulated facilitative glucose transporter
Glut-1, alongside the associated upregulation of glycolytic enzymes
(Airley and Mobasheri, 2007). Metabolomic analysis also indicates
that Glut-1 facilitates a HIF-1-independent rise in the production
of metabolites associated with phospholipid metabolism and cell
turnover, for example phosphatidyl choline (Evans et al, 2008).
The sequence homology between the ChRE and the hypoxia
response element (HRE) in the promoter of HIF-1 target genes,
meanwhile, suggests that there may be a cross-talk or at least
coordination of ChREBP and HIF-1-regulated pathways within the
spatially and temporally heterogeneous tumour microenvironment
(Dang et al, 1997).
So far, much of the work surrounding ChREBP has focussed on
its function as a liver transcription factor, its activation by glucose
metabolites and role in the regulation of lipogenesis. This may have
implications for breast cancer pathology. First, breast cancer is
mechanistically and epidemiologically linked with obesity (Calle
and Kaaks, 2004; Lorincz and Sukumar, 2006), suggesting a causal
link with deregulated lipid metabolism. Second, glycolytic and
lipogenic pathways may behave as integrated features of tumour
metabolism brought about via loss of p53, activation of Akt and
changes in the expression and functionality of lactate dehydro-
genase (Young and Anderson, 2008).
The aim of this study was to investigate ChREBP expression in
breast cancer and how this may be associated with Glut-1
expression and malignant progression in the context of published
genomic analysis of the hypoxic tumour microenvironment.
MATERIALS AND METHODS
Materials. Unless stated otherwise, all reagents were obtained
from Sigma (Dorset, UK). Histology glass wear and mounting
medium were purchased from Thermo Scientific (Loughborough,
UK). Cell lines were obtained from ATCC (Teddington, UK) (LGC
standards) and had been authenticated according to in-house
procedures.
Tissue microarrays. Tissue microarrays used in this study
included the Accumax (Cepheid UK Ltd, Stretton, UK) (A712)
breast cancer test array that carried samples from 12 cases of breast
cancer paired with normal adjacent tissue. In addition, two
separate breast cancer progression arrays were also used: the
Cybrdi Inc (Rockville, MD, USA, CC08-00-005) array that
contains 71 individual cases of adenosis, fibroadenoma, tumour
to metastasis, and the Biomax (Insight Biotechnology, Wembley,
Middlesex, UK, BR2082) array that contains a total of 206 cases
made up of 32 samples of metastatic carcinoma, 68 invasive ductal
carcinoma, 22 each of lobular carcinoma and intraductal
carcinoma, 4 each of squamous cell carcinoma and lobular
carcinoma in situ, 8 fibroadenoma, 16 each of hyperplasia and
inflammation, 10 adjacent normal tissue and 6 normal tissue.
Information on clinical and pathological characteristics as well as
ethical considerations is available on the website of, or upon
request from, the commercial tissue microarray suppliers. These
studies were carried out after approval by the institutional ethical
review committee (University of Huddersfield, Huddersfield,
USA).
Immunohistochemistry. Immunohistochemistry was carried out
as per established protocols, with primary antibody steps consisting
of a 1 : 100 dilution of rabbit anti-Glut-1 (Alpha Diagnostic
International, San Antonio, TX, USA) or a 1 : 400 dilution of rabbit
anti-ChREBP (Abcam, Cambridge, UK). For ChREBP immunos-
taining, antigen retrieval was carried out by boiling slides for
20min in 10mM citrate buffer. A commercially available kit
(Menorini Diagnostics, Reading, UK) that consists of a universal
rabbit/mouse secondary probe and a horseradish peroxidase or
alkaline phosphatase enzyme polymer conjugate plus chromogen
was used for visualisation.
Antibody specificity. The specificity of the rabbit anti-ChREBP
used for the immunohistochemical analysis of the tissue micro-
arrays was determined by western analysis of a ChREBP knock-
down cell line generated from MCF-7 cells. This revealed a sharp
decrease in expression in early passages with a return to wild-type
levels within five passages. This apparent reversal of knockdown
was confirmed by qRT–PCR analysis (shown in Supplementary
Figure S1). Although this confirms the specificity of the antibody,
further work will be needed to determine whether the changes in
ChREBP expression relates to a technical problem with the
generation of the cell lines or is a biological adaptation to reduced
ChREBP expression.
The ChREBP knockdown MCF-7-derived cell line and sub-
sequent western and qRT–PCR analyses were carried out.
Generation of ChREBP knockdown MCF7-derived cell line.
A ChREBP knockdown cell line and scrambled vector control were
generated using reagents obtained from Santa Cruz Biotechnology
(Dallas, TX, USA). MCF7 cells were transfected with CHREBP
shRNA (h) lentiviral particles (sc-38617-V) using Polybrene
(Sigma) as per the manufacturer’s protocol. These were used
alongside control shRNA lentiviral particles (sc-108080). Stable
clones were selected after placing in DMEM containing 2 mgml 1
puromycin (Santa Cruz Biotechnology).
Western blot. Cell lysates were prepared according to standard
protocols and the equivalent to 20 mg protein samples was run on
NuPAGETM Novex electrophoresis pre-cast gels (Invitrogen,
Life Technologies, Paisley, UK) followed by transfer onto a PVDF
transfer membrane of pore size 0.45 mm (Immobilon-P Polyviny-
lidine difluoride, Millipore, Watford, UK). Membranes were
blocked with 1% (w/v) casein before overnight incubation at 4 1C
with rabbit anti-ChREBP diluted with SignalBoostImmunoreaction
Enhancer primary antibody solution (Merck Chemicals, Watford,
UK) according to the manufacturer’s instructions. The membranes
were visualised using an Odyssey Infra-red Imaging system
(Li-Cor, Lincoln, NE, USA), using b-actin antibody as a loading
control.
qRT–PCR analysis. Total RNA was extracted using Tri Reagent
(Sigma) as per the manufacturer’s instructions. The quantities and
qualities of RNA from each sample were assessed by gel agarose
electrophoresis as well as spectrophotometry using a NanoDrop
2000 (Thermo Scientific). Then, 1 mg of RNA was incubated in a
total volume of 10 ml containing 1ml of 10 DNase I reaction
buffer and 1 ml (1U ml 1) of DNase I at 37 1C for 30min with
subsequent inactivation at 65 1C for 15min with 1ml 25mM EDTA.
The cDNA was synthesised in a 20 ml volume with oligo(dT)20
(Invitrogen) and SuperScript III First-Strand Synthesis SuperMix
(Invitrogen). The reactions were incubated at 50 1C for 1 h and
then inactivated by heating at 70 1C for 15min. The RNase H
(Invitrogen) was added, 1 ml (1 Uml 1) to each preparation, and
incubated for 20min at 37 1C.
In each qRT–PCR reaction, 5 ng of template cDNA was used in
a total volume of 15 ml containing water, 7.5 ml of iTaq Universal
SYBR Green 2x Supermix (Bio-Rad, Herts, UK) and the
appropriate primer set (Eurofins MWG Operon, Ebersberg,
Germany; see Supplementary Information for primer sequences)
at a final concentration of 100 nM. The qRT–PCR assays were
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performed on a Bio-Rad CFX96 Touch Real-Time PCR Detection
System using the following PCR conditions: 15min at 95 1C
followed by 50 cycles of 15 s denaturing at 95 1C and 60 s annealing
at 60 1C. A reverse transcriptase negative control was used to assess
whether any residual genomic DNA remained and a no-template
control was included to examine primer-dimer formation. The qRT–
PCR experiments were excluded for analysis if the reaction
efficiency was outside the range of 0.9–1.1 or if the r2 value of the
linear regression was o0.95. For the qPCR analysis, the relative
normalised expression (DDCq) method was determined using
RPL30 as a reference gene. The normalised data from the various
cell lines were analysed using the Bio-Rad CFX manager software
3.0 and fold change determined.
Semiquantitative and statistical analysis. Semiquantitative
scoring was carried out as in previous studies (Evans et al, 2008)
where, briefly, tissue microarray sample ‘spots’ were viewed at low
magnification ( 200) and an overall score assigned according to
intensity and area of immunostaining staining. Supplementary
Figure S2 shows representative examples of sample scoring as
follows: 0, no; 1, light; 2, moderate; and 3, heavy staining.
To determine interobserver variation, the first 30 samples of the
Biomax (BR2082) array were scored by two observers (REA and
WA-T) (ChREBP r¼ 0.854, Po0001, n¼ 30); the intraobserver
variation was measured using scores made by the primary observer
(WA-T) on the Biomax (BR2082) array 3 weeks apart (Spearman’s
rank correlation: (Glut-1) r¼ 0.843, Po0.001, n¼ 32 (ChREBP)
r¼ 0.952, Po0.001, n¼ 32).
Bioinformatic analysis. The derivation of a common hypoxia
signature or ‘hypoxia metagene’, together with a breast cancer-
specific hypoxia signature, has been described previously and may
be used to provide both prognostic information in the clinic. It also
provides data that allow us to integrate gene function and derive
further hypotheses with which to investigate how pathways
directed by hypoxia are associated with deregulated metabolism
within the tumour microenvironment (Favaro et al, 2011; Buffa
et al, 2011). These have been used to compile up- and down-
regulated hypoxia gene signatures using in vitro and in vivo data
sets that charted changes in the expression of these genes in
hypoxic conditions alongside the involvement of hypoxia-inducible
factor HIF-1. A large number, although not all, of these hypoxia-
regulated genes are HIF-1 target genes (Buffa et al, 2010).
The Oxf-IJB breast cancer series and other published data sets
were used for expression analysis and have been described
previously (Buffa et al, 2011). For comparison, this included the
Curtis breast cancer series of 2136 breast tumours (Curtis et al,
2012) via Oncomine (Compendia Biosciences, Ann Arbor,
MI, USA).
RESULTS
ChREBP immunohistochemistry in tissue microarrays. Immu-
nohistochemical profiling of ChREBP protein expression in tissue
microarrays was carried out to determine whether there is
differential expression in breast tumours of mixed pathologies
relative to adjacent nonmalignant breast tissues. The overexpres-
sion of Glut-1 observed in breast and other cancers (Avril et al,
2001; Airley et al, 2010) may provide glucose metabolites with
which to activate ChREBP signalling, and therefore we also carried
out Glut-1 immunohistochemical analysis in the same tissue
microarrays to observe any colocalisation and correlation between
Glut-1 and ChREBP. In general, ChREBP immunostaining was
found in the cytoplasm and the nucleus. The subcellular location in
the nucleus is because of dephosphorylated (active) ChREBP,
wherein it is capable of forming a DNA-binding complex
(Ma et al, 2005).
Initially, we used a low-density tissue microarray (Accumax
A712) to look for any differences in the pattern of ChREBP
expression between breast tumours and adjacent normal tissue that
would allow preliminary assessment of ChREBP as a biomarker of
malignancy in this tissue type (Figure 1). The data from this array
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Figure 1. Immunohistochemical staining carried out according to the area and intensity of staining (0, absent; 1, light; 2, moderate; 3, heavy
staining. (A) The ChREBP staining (Fast Red, pink) in malignant breast compared with an absence of staining in normal adjacent tissue (B) in a test
issue microarray (Accumax A712). In cases where normal tissue stained positively for ChREBP, this was at a lower level in both area and intensity.
At places where this took place, Glut-1 (DAB, brown) in serial sections was similarly localised (C and D), whether in duct or stromal tissue (shown by
arrows). Scale bar¼100mm. The full colour version of this figure is available at British Journal of Cancer online.
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showed 5 out of 12 cases clearly expressing ChREBP protein in
malignant but not adjacent normal tissue, but 7 out of 12 cases
stained positive for ChREBP in both, although the ChREBP
staining was at a lower level in normal tissue when present. There
was a similarity in localisation between ChREBP and Glut-1
expression in serial sections found in areas of both normal and
malignant breast tissue.
To reveal a possible link between ChREBP protein and the
histopathology of malignant progression, we used two commer-
cially available breast progression arrays that provided us with
samples from two independent series of breast cancer cases.
Figure 2 shows representative ChREBP immunostaining in the
Cybrdi (CC08-00-005) breast progression array, where staining
scores showed a clear trend for increasing with the malignant
progression as defined by histopathological diagnosis. Although
nonmalignant and inflammatory or hyperplastic tissue tended not
to express ChREBP and, if so, at low levels, malignant, infiltrating
and metastatic breast tumour tissue was virtually always associated
with moderate or heavy ChREBP staining. A similar trend was seen
with the Biomax (BR2082) array that also carried a progression of
breast histopathologies but with a larger series of cases. In this
series, moderate or heavy ChREBP staining was only apparent in
invasive tumours, whereas normal tissue, nonmalignant hyperpla-
sia and carcinoma in situ, in all but 2 cases, showed no ChREBP
staining at all. Furthermore, Glut-1 and ChREBP scores were
significantly correlated (Spearman’s rank correlation: r¼ 461,
Po0.001, n¼ 207). Categorisation into normal, benign hyperplas-
tic/inflammatory, in situ (localised), invasive and metastatic
histopathology produced a statistically significant increase in mean
immunohistochemical score in both the Cybrdi and Accumax
progression arrays, although a significant reverse trend was
observed when considering mean ChREBP mRNA expression
and malignant progression by similar histopathological designation
in the Curtis series of breast cancer cases (2136 patients) via
Oncomine (Figure 3A).
Clinical correlates of ChREBP protein and mRNA expression
with survival. Kaplan–Meier analysis did not show a significant
relationship between grouped ChREBP protein scores in the
Oxf-IJB breast cancer series with either overall (P¼ 0.1) or relapse-
free (P¼ 0.6) survival in this cohort of patients. However, an
analysis of survival data from the Curtis series showed ChREBP
mRNA expression to not only be significantly correlated with
increased survival (log rank Po0.001; MLXIPL ILMN_1722073;
Figure 3B) but also show a trend for decreased expression with
grade and an overexpression in normal adjacent tissue and benign
cases relative to malignant tissue (illustrated by heat maps
generated via Oncomine, see Supplementary Slides). A similar
trend for increased survival was observed with the ChREBP
reporter MLXIPL ILMN_2399919 but this was not significant
(P¼ 0.091). When stratified by molecular subtype, there remained
a significant increased likelihood of survival with high ChREBP
(MLXIPL ILMN_1722073) mRNA expression in oestrogen receptor
(ER)-positive cases (log rank P¼ 0.014), ErbB2-negative (log rank
P¼ 0.004) and nontriple-negative (log rank Po0.001) breast
cancer. A differential analysis of ChREBP expression by ER status
via Oncomine also revealed a significant overexpression (MLXIPL
ILMN_1722073 1.082-fold change, t-test: 6.219, P¼ 4.02E–10;
ILMN_2399919, t-test: 4.629, P¼ 2.17E–6) in a subgroup of
ER-positive invasive ductal breast carcinoma within the Curtis
breast series.
Clinical correlates of ChREBP protein and mRNA expression
with hypoxia. Analysis of the relationship between ChREBP
expression and the breast hypoxia gene signature revealed a
significant correlation between ChREBP protein and mean
‘downregulated’ hypoxia scores (r¼ 0.3, P¼ 0.014, n¼ 67), which
was weaker but consistent at mRNA level (r¼ 0.134, P¼ 0.2,
n¼ 67) There was also a significant anticorrelation between
ChREBP protein and median ‘upregulated’ hypoxia scores
(r¼  0.246, P¼ 0.04, n¼ 67). There was, however, no relation-
ship to scores derived from either the up- or downregulated lactate
signature described by Chen et al (2008).
The ChREBP mRNA levels mined from an extended series of
232 cases analysed using an Illumina (San Diego, CA, USA)
platform correlated significantly with both mean and median
100 M 100 M
100 M
Figure 2. The ChREBP protein staining (Fast Red) in a human breast cancer progression array (Cybrdi CC08-00-005), showing a clear trend for
increased staining score with malignant progression from normal breast to metastatic breast cancer. (A) Normal breast (score 0); (B) mild atypical
ductal hyperplasia (score 1); (C) intraductal carcinoma (score 2); and (D) metastatic nonspecific infiltrating ductal carcinoma (score 3). Scale
bar¼100mm.
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‘downregulated’ hypoxia scores, and as expected remained antic-
orrelated with mean and median ‘upregulated’ hypoxia scores
(Figure 4). In the same data set, ChREBP mRNA was also
anticorrelated with individual hypoxia-inducible genes such as CA9
(r¼  0.215, P¼ 0.001) and LDHA (r¼  0.213, P¼ 0.001) and,
in contrast with the significant positive correlation shown by
protein forms in the BRC 711 tissue microarray, ChREBP and
Glut-1 mRNA in the Illumina data set were also significantly
anticorrelated (r¼  0.212, P¼ 0.001). A similar anticorrelation
between ChREBP mRNA expression and these hypoxia-regulated
genes was observed qualitatively in the Curtis breast series, as
shown in heat maps generated via Oncomine (Supplementary
Slides) and in an extended correlative analysis (Supplementary
Table S1).
Correlates of ChREBP mRNA with ChREBP target genes. Jeong
et al (2011) carried out a comprehensive ChIP sequence analysis
of ChREBP target expression in human hepatocellular carci-
noma HEPG2 cells and we used these to analyse the human
breast cancer data sets. Table 1 shows the correlative relation-
ships existing within the Oxf-IJB (Illumina) series of 232
patients between the level of ChREBP mRNA and that of its
target genes previously identified by Jeong et al (2011). This was
with the aim of highlighting any functional similarities or
differences in the nature of ChREBP signalling in the
hepatocellular carcinoma cell line used by Jeong et al (2011)
and breast cancer. ChREBP mRNA expression, mined from the
Illumina data set, correlated positively with the expression of all
genes identified in the study of Jeong et al (2011) as upregulated
by ChREBP apart from pyruvate dehydrogenase kinase 2 (PDK2).
For genes identified as downregulated by ChREBP, although
ChREBP mRNA mined from the Illumina data set mostly
showed concordant negative regulation of these target genes,
there was a positive correlation with the expression of
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Figure 3. (A) There was a statistically significant (one-way ANOVA) trend whereby mean (median shown in brackets) ChREBP IHC score
increased with malignant progression, consistent for both the Cybrdi and Accumax breast cancer progression arrays. In contrast, however,
ChREBP mRNA expression data (log2 median-centred intensity) mined from the Curtis breast series showed a clear and significant decrease with
malignant progression. Further analysis (B) of Curtis breast series showed high (Xmedian 0.1265 log2 median-centred intensity) vs low ChREBP
(MLXIPL ILMN_1722073) mRNA expression to be a significant predictor of 5-year disease-specific survival (log rank P-value also shown).
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phosphoenolpyruvate carboxykinase (PEPCK). The distribu-
tions of these data in relation to median expression of all
mRNAs in the Illumina data set are presented as box-and-
whisker plots in Figure 5. A strongly significant positive
correlation between ChREBP and PEPCK was also found in
the analysis of the Curtis breast series (Supplementary Table S1).
DISCUSSION
So far, there has been limited investigation of a possible role for
ChREBP in tumour pathology or as a biomarker of malignancy.
One previous study has shown no relationship between single-
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Figure 4. Scatter plots illustrating negative Spearman’s rank correlations between ChREBP mRNA expression and (A) mean ‘upregulated’
hypoxia score (r¼  0.343, P¼ 8.279e 08, n¼ 232); (B) median ‘upregulated’ hypoxia score (r¼ 0.31, P¼ 8.449e 07, n¼ 232); and positive
correlations with (C and D) mean (r¼0.318, P¼ 7.268e 07, n¼232) and median (r¼0.378, P¼2.594e09, n¼ 232) ‘downregulated’ hypoxia
scores (obtained from the Illumina Array data set from extended Oxf-IJB series).
Table 1. Spearman’s rank correlations between carbohydrate response element-binding protein (ChREBP) and target genes previously identified by
Jeong et al (2011), drawn from mRNA data mined from the breast cancer (n¼232) Oxf-IJB [Illumina] data set
Gene symbol Description Gene ID R (P-value) Oxf-IJB [Illumina] data set
PKLR Pyruvate kinase, liver and RBC NM_181871 [GI_32967596-A] 0.0453 (0.492)
[GI_32967596-I] 0.0247 (0.709)
SREBP1c or SREBF1 Sterol-regulatory element-binding transcription factor 1 NM_001005291 0.00517 (0.938)
DGAT2 Diacylglycerol O-acyltransferase homolog 2 (mouse) NM_032564 0.487 (3.141e 15)
PDK2 Pyruvate dehydrogenase kinase, isozyme 2 NM_002611 0.137 (0.0370)
SCD1 Stearoyl-CoA desaturase (d-9-desaturase) NM_005063 0.208 (0.00147)
GPDI or GPD1 Glycerol-3-phosphate dehydrogenase 1 (soluble) NM_005276 0.595 (2.2e 16)
TXNIP Thioredoxin interacting protein NM_006472 0.465 (7.58e 14)
INHBE Inhibin, bE NM_031479 0.154 (0.0189)
SLC6A9 Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 NM_006934 0.0866 (0.189)
PEPCK or PCK1 Phosphoenolpyruvate carboxykinase 1 (soluble) NM_002591 0.565 (o2.2e16)
G6Pase or G6PC Glucose-6-phosphatase, catalytic subunit NM_000151 0.0237 (0.720)
TRIB3 or C20orf97 Tribbles homolog 3 (Drosophila) NM_021158 0.224 (0.000573)
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nucleotide polymorphism of either ChREBP or FASN and breast
cancer risk (Campa et al, 2009). The differential staining between
normal adjacent and malignant tissue, as well as the clear increase
in de novo expression of ChREBP protein with malignant
progression, therefore suggests that local rather than genomic
changes in ChREBP may have a role in driving tumourigenesis.
It is puzzling that the majority of ChREBP expression appeared to
be the cytoplasmic, phosphorylated and therefore inactive
transcription factor. However, ChREBP exists in multiple isoforms
that might vary in their tissue and tumour specificity as well as
their up- and downstream regulatory effects. One recent study
identified a regulatory path existing between the canonical
ChREBPa isoform and ChREBPb, where ChREBPb is induced
by ChREBPa via an alternative promoter in adipose tissue and
predicts insulin sensitivity. This suggests that there might be not
only an element of cross-talk between malignant breast and
surrounding normal adipose tissue, but also that de novo synthesis
of ChREBP may be partially self-regulated and critical to the
changes in insulin-signalling that are a feature of breast tumour
pathology and linked with cell proliferation and survival. The
ChREBP association with insulin signalling and the correlation we
have observed with Glut-1 may also determine how it interacts
with important breast tumourigenic pathways such as the ER,
epidermal growth factor receptor (EGFR), the insulin-like growth
factor (IGF) systems and the mammalian target of rapamycin
(mTOR) pathways (Martin and Baxter, 2007; Weichhaus et al,
2012; Yang and Yee, 2012).
Relationship between ChREBP protein and mRNA expression.
The major function of ChREBP is the regulation of lipogenesis.
However, HIF-1 and ChREBP share a function; to carry out their
respective control of catabolic and anabolic pathways, they
upregulate the expression of glycolytic genes. This increased rate
of glycolysis is limited by a negative feedback mechanism mediated
by the induction of TXNIP (thioredoxin interacting protein),
a feedback mechanism common to both transcription factors (Yu
et al, 2010). Much of the understanding of the mechanistic effects
of ChREBP has come about through studies involving cultured
hepatocytes, where it has been observed that polyunsaturated but
not saturated or monounsaturated fats suppress de novo synthesis
of ChREBP, and that overexpression of ChREBP abolishes this
effect (Dentin et al, 2005a). In addition, ChREBP is deactivated via
activation of adenosine monophosphate-activated kinase (AMPK)
that takes place in conditions where the AMP/ATP ratio is high,
a consequence of increased diversion of the end products of
glycolysis into fatty acid synthesis rather than oxidative phosphor-
ylation (Hebbachi and Saggerson, 2013). Therefore, the existence
of a negative feedback mechanism, although a complex one, where
the induction of fatty acid synthesis by active nuclear ChREBP
leads to eventual suppression of ChREBP mRNA synthesis, but
where initial activation of existing ChREBP necessitates
an increased rate of glucose uptake and metabolism, may exist.
In breast tumours, this mechanism may be dependent upon the
bioenergetic flux brought about by interacting populations of
normoxic and hypoxic tumour and adipose tissue. The apparent
inversion of the effects of ChREBP protein and mRNA on breast
cancer progression, survival and the expression of hypoxia-
regulated genes may be a reflection of such a mechanism.
Relationship between ChREBP and a normoxic malignant
phenotype. Using a metabolomic approach, we have shown in a
previous study that hypoxic conditions, particularly in the absence
of an intact HIF-1 response, are countered by a rise in the AMP/
ATP ratio and the subsequent activation of the glycolytic enzyme
phosphofructokinase (PFK-1) and AMPK (Golinska et al, 2011).
The rise in the AMP/ATP ratio is also a key regulatory feature of
AMPK-activated phosphorylation and inactivation of ChREBP,
a feedback mechanism that downregulates ChREBP transcription
in response to ChREBP-induced fatty acid synthesis (Kawaguchi
et al, 2001; Fujii et al, 2006). The current findings highlight a
correlation between ChREBP expression and the downregulated
breast hypoxia signature, suggesting that ChREBP is expressed in
normoxic conditions and a possible link with the suppression
or downregulation of hypoxia and HIF-1-regulated genes.
One explanation may be that, in hypoxic conditions, the activation
of AMPK leads to downregulation of ChREBP and consequently
fatty acid synthesis, favouring instead the B-oxidation pathway,
where excess fatty acids may be broken down and fed back into the
Krebs cycle. In normoxic conditions, however, the accumulation of
pyruvate and subsequent conversion to acetyl CoA will feed into
the first committed steps of ChREBP-inducible fatty acid synthesis.
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Figure 5. Box plot illustrating the distribution (median, upper, lower,
25th, 75th percentiles and outliers) of mRNA expression (log2 median-
centred intensity) of genes identified previously as ChREBP targets
upregulated (A) and downregulated (B) in the study of Jeong et al
(2011), mined from the breast cancer Oxf-IJB (Illumina) data set
(n¼232). Correlations with PKLR (puruvate kinase) were drawn from
data mined using both the (GI_32967596-A) and (GI_32967596-A)
identifiers (see Table 1 for correlations and P-values).
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This hypothesis is supported by the evidence of an anticorrelation
between ChREBP mRNA and PDK2 (Table 1) that may be
indicative of PDK2 suppression brought about by aerobic
conditions within the breast tumour microenvironment that will
in turn favour the conversion of pyruvate into acetyl CoA via
its downstream effect on the activation of pyruvate kinase
(Contractor and Harris, 2012). Also, PDK2 increases accumulation
of HIF-1 that may reflect the competing influences (Sun et al,
2009). The anticorrelation with the insulin modulator TRIB3,
which is activated in hypoxic conditions and is associated with
increased production of lactate and increased extracellular lactate
levels, would also fit with this hypothesis (Mazzio et al, 2012).
Interestingly, as with ChREBP in this study, TRIB3 in its protein
and mRNA forms are oppositely associated with breast cancer
prognosis. Despite TRIB3 being hypoxia inducible, this effect is
linked to an inhibition of protein translation and redistribution of
mRNA to areas within the cell that are less densely packed with
ribosomes, which also takes place under anoxic conditions
(Wennemers et al, 2012). Further work would be needed to
determine whether a similar response explains the opposite
association observed with ChREBP.
ChREBP as a mediator of alternative metabolic pathways in
breast tumourigenesis. In hepatic tissue, ChREBP, together with
sterol regulatory element-binding protein (SREBP), regulates
glycolytic and lipogenic gene expression synergistically by input-
ting a response to increased glucose flux (Dentin et al, 2005b).
Increased SREBP-mediated expression of FASN has been observed
in hypoxia-exposed breast tumour cell lines alongside colocalisa-
tion of SREBP with the hypoxic regions of tumours (Furuta et al,
2008). This suggests that although SREBP and ChREBP share
functional similarities, their dominance may depend upon
the pattern of tumour oxygenation. Further evidence that the
induction or suppression of ChREBP target genes may follow a
different path in the breast tumour microenvironment from that of
hepatic tissue is shown by the positive correlation between
ChREBP mRNA and the gluconeogenic enzyme PEPCK that was
suppressed in the presence of active ChREBP in the hepatocellular
carcinoma cell line investigated by Jeong et al (2011). If, as the data
of this study suggest, ChREBP is linked with normoxia, increased
PEPCK expression in these conditions might correspond with the
increased glucose demand of highly glycolytic but normoxic
tumour tissue. This demand would potentially require supplemen-
tation via increased gluconeogenesis rather than via hypoxia-
induced Glut-1 glucose transport. In contrast, in normal liver
regeneration, PEPCK expression is itself increased via a hypoxia-
driven HIF-1-dependent pathway (Tajima et al, 2009) unavailable
in normoxic conditions.
In conclusion, our work suggests that the uptake of glucose to
support a highly glycolytic phenotype in hypoxic conditions might
be the primary role of glut-1 in tumours, but a secondary role is to
support the diversion of glycolytic end products into fatty acid
synthesis in aerobic conditions. The resulting changes in tumour
metabolism may then favour activation of downstream tumouri-
genic pathways via activation of ChREBP-induced target genes.
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